We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elimination of CSCs as Potential Cure for Colon Cancer

By LabMedica International staff writers
Posted on 29 Jan 2018
Cancer researchers have identified a molecular pathway required by the cancer stem cells that underlie growth and development of colorectal tumors.

Colon cancer is a heterogeneous tumor driven by a subpopulation of cancer stem cells (CSCs). More...
To study CSCs in colon cancer, investigators at Charité - Universitätsmedizin Berlin, Germany) used limiting dilution spheroid and serial xenotransplantation assays in mice to functionally define the frequency of CSCs in a panel of patient-derived cancer organoids. The aim was to eventually arrive at a treatment option that would cure colon cancer through the targeted elimination of cancer stem cells.

Results published in the December 5, 2017, issue of the journal Cell Reports showed that cancer organoids were enriched for CSCs, which varied in frequency between tumors. Whole-transcriptome analysis identified the WNT and Hedgehog signaling pathways as being enhanced in CSC-enriched tumors and in aldehyde dehydrogenase (ALDH)-positive CSCs. Furthermore, they showed that non-canonical Hedgehog signaling was a positive regulator of WNT signaling and was required for colon CSC survival.

"The targeted inhibition of the Hedgehog signaling pathway, used in combination with other standard treatments to shrink tumors, may provide a new strategy for the elimination of cancer stem cells and the prevention of cancer recurrence," said first author Dr. Joseph Regan, a researcher at Charité - Universitätsmedizin Berlin. "Future research will set out to better define the downstream signaling components of the pathway and further investigate how Hedgehog signaling controls cancer stem cell survival."

Related Links:
Charité - Universitätsmedizin Berlin


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.